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Abstract
Objective—Driving under the influence of drugs is a global traffic safety and public health 
concern. This trend analysis examines the changes in general drug usage other than alcohol, broad 
categories, and typical prescription and illegal drugs among drivers fatally injured in motor 
vehicle crashes from 1999-2010 in the U.S.
Methods—Data from the Fatality Analysis Reporting System were analyzed from 1999-2010. 
Drug prevalence rates and prevalence ratios (PR) were determined comparing rates in 2009-2010 
to 1999-2000 using a random effects model. Changes in general drug usage, broad categories, and 
representative prescription and illegal drugs including, methadone, oxycodone, hydrocodone, 
barbiturates, benzodiazepines, and cocaine, were explored.
Results—Comparing 2009-2010 to 1999-2000, prevalence of drug usage increased 49% 
(PR=1.49; 95% confidence interval [CI] 1.42, 1.55). The largest increases in broad drug categories 
were narcotics (PR=2.73; 95% CI 2.41, 3.08), depressants (PR=2.01; 95% CI 1.80, 2.25), and 
cannabinoids (PR=1.99; 95% CI 1.84, 2.16). The PR was 6.37 (95% CI 5.07, 8.02) for 
hydrocodone/oxycodone, 4.29 (95% CI 2.88, 6.37) for methadone, and 2.27 (95% CI 2.00, 2.58) 
for benzodiazepines. Barbiturates declined in rate over the 12-year period (PR=0.53; 95% CI 0.37, 
0.75). Cocaine use increased until 2005 then progressively declined, though the rate remained 
relatively unchanged (PR=0.94; 95% CI 0.84, 1.06).
Conclusions—While more drivers are being tested and found drug-positive, there is evidence 
that a shift from illegal to prescription drugs may be occurring among fatally injured drivers in the 
U.S. Driving under the influence of prescription drugs is a growing traffic concern.
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1. Introduction
Motor vehicle collision remains one of the leading causes of injury mortality in the U.S. 
(Rockett et al. 2012). Research suggests that driving under the influence of drugs other than 
alcohol is a growing public health (Walsh et al. 2004) and global traffic safety concern 
(Morland 2000, Movig et al. 2004). In the U.S., the prevalence of drug-involved driving was 
estimated to be 11%-14% in 2007 (Lacey et al. 2009).
Driving under the influence of either illegal drugs or prescription medications may lead to 
driver impairment and/or an increased risk of motor vehicle collision. In regards to illicit 
substances, there are inconsistencies in the research concerning stimulants, such as cocaine 
or amphetamines, and driver cognizance (Kelly et al. 2004). As for prescription 
medications, benzodiazepines have been linked to an increased risk of motor vehicle 
collision (Walsh et al. 2004). There is evidence that those taking prescription opioids, such 
as oxycodone or hydrocodone, may be at an increased risk of traffic crash (Orriols et al. 
2009). Contrarily, for the opioid methadone, there is no increased risk of motor vehicle 
collision associated with long term usage (Ogden and Moskowitz 2004).
The specific drugs consumed by fatally injured drivers and changes in their use over time 
throughout the U.S., including the role of prescription medications, have been largely under 
studied. Findings from the 2007 U.S. National Roadside Survey indicated that the 
occurrence of prescription narcotics, particularly the opioids oxycodone, hydrocodone, and 
methadone, and depressants, such as benzodiazepines, were common among those that drive 
under the influence with a prevalence of 1.2%-3.3% and 2.4%-3.4%, respectively (Lacey et 
al. 2009). Findings from the 2007 National Roadside Survey also suggested that 
cannabinoids and cocaine were common among those that drive under the influence (Lacey 
et al. 2009). Even though cannabinoids were more prevalent than cocaine amongst drivers 
under the influence (Lacey et al. 2009), cannabis has been legalized for medicinal use in 
several states (Koepsell et al. 1994), making it not entirely illegal. Therefore, cocaine is 
likely more representative of illicit drug use amongst those who drive under the influence as 
it a controlled substance typically not available outside of a healthcare institution.
Because of the potential for impairment and the prevalence of substance use amongst 
drivers, there is a need to discern how drug use is trending for public health intervention. 
Therefore, the purpose of this study is a trend analysis to examine the changes in drug use 
among fatally injured drivers in motor vehicle crashes from 1999 to 2010 in the U.S. 
Particular interest is given to changes in general drug usage, broad categories of drugs, and 
representative prescription medications and illegal substances including depressants, 
specifically benzodiazepines and barbiturates, opioids, explicitly methadone, hydrocodone, 
and oxycodone, and cocaine.
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The data for this analysis were obtained from the Fatal Analysis Reporting System (FARS). 
FARS is a publically available database maintained by the National Highway Traffic Safety 
Administration (NHTSA) (National Highway Traffic Safety Administration 2012). States 
report motor vehicle crashes to the NHTSA when at least one person involved in the 
collision dies within thirty days of the incident (National Highway Traffic Safety 
Administration 2012). Using strict quality control procedures, trained NHTSA analysts 
extract data from the state reported files (National Highway Traffic Safety Administration 
2012). Consequently, the FARS database contains detailed information relating to the crash, 
vehicles, and people involved (National Highway Traffic Safety Administration 2012). As 
part of the reporting process, up to three drug test results per individual involved in the 
traffic collision can be documented in addition to a blood alcohol concentration; drugs 
administered after the collision are excluded from drug test results (National Highway 
Traffic Safety Administration 2010, 2012). Drug tests administered to drivers can be 
accomplished via urine drug screens, blood, or combination (i.e. urine and blood tests) post-
collision.
States differ in their consistency of drug testing. Not all fatally injured drivers are tested for 
drugs and alcohol and not all states consistently report their results. For example, in the 
FARS database from 1999 to 2010, the average drug testing percent of all states combined 
was approximately 48%. Over the 12-year time span, the average overall drug testing 
percent of individual states ranged from 1% (Maine) to 90% (Hawaii) (National Highway 
Traffic Safety Administration 2010, 2012).
2.1.1 Study population—Because of the differences in states’ drug testing and 
consistency of reporting, there were data quality concerns. A comprehensive analysis was 
conducted on each state regarding overall drug testing percentage of fatally injured drivers, 
percent of their population testing positive for drugs, and the proportion of drug results listed 
as ’Other’. To be included in this analysis, a state must have a drug testing percent ≥ 50%. If 
the state's drug positive rate was high (i.e. >70%) or low (<5%) and/or proportion of drug 
results listed as ‘Other’ was high (>70%), the state was excluded as this may have indicated 
a data quality issue. The following states met the inclusion criteria: Arizona, California, 
Colorado, Georgia, Hawaii, Illinois, Kentucky, Maryland, Massachusetts, Nevada, New 
Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Pennsylvania, 
Rhode Island, South Carolina, Vermont, Virginia, Washington, West Virginia, and 
Wyoming. Analyses were limited to all fatally injured drivers who died between January 1st, 
1999 and December 31st, 2010 with a known drug test result from states meeting the 
inclusion criteria.
2.2 Statistical analysis
Descriptive characteristics of drivers testing positive for at least one drug were compared to 
drivers testing negative. Statistical significance of nominal data was determined thru 
Pearson's Chi Square Tests or Cochran-Mantel-Haenszel statistics. Cochran-Armitage Trend 
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tests with Modified Ridit scoring were performed on all ordinal data. Descriptive 
characteristics included age, gender, race, ethnicity, number of vehicles involved, a driving 
while intoxicated (DWI) conviction within the past 3 years, a previous crash within the past 
3 years, blood alcohol concentration (BAC), the type of drug test administered, day, time, 
and year of the crash, how long the individual survived after the crash, and if they were a 
professional driver (i.e. held a commercial drivers license). With the exception of the 
variables indicating the type of drug test administered, professional driver status, and 
survival time, all variables were characterized similarly to previously published work (Brady 
and Li 2013). The type of drug test administered post-collision was categorized as a urine, 
blood, or combination test. Professional driver status was dichotomized. Survival time was 
dichotomized into death within one hour of collision or beyond.
BAC, measured in grams per deciliter (g/dl), was based on multiple imputed BAC levels 
determined by NHTSA (National Highway Traffic Safety Administration 2012). The 
NHTSA has previously published extensive literature on their multiple imputation methods 
of missing BAC for drivers involved in fatal traffic collisions (Rubin et al. 1998, 
Subramanian 2002). If BAC was missing for a driver, the NHTSA's validated model would 
impute 10 specific values of BAC across a range of possible values permitting the 
estimation of statistics including measures of central tendency and dispersion (Rubin et al. 
1998, Subramanian 2002). Therefore, the overall estimate of BAC value was generated from 
10 imputations, and PROC MIANALYZE in SAS was used to combine estimates.
Prevalence and prevalence ratios were calculated for drug presence among all fatally injured 
drivers with a known drug test result for each of the variables described using log binomial 
regression. The prevalence ratio was shown to quantify whether the demographic 
characteristic was associated with either an increased or decreased occurrence of a drug 
positive result compared to a referent sub-group. Age 25-34, male gender, white race, non-
Hispanic ethnicity, possessing a non-commercial driver's license, blood alcohol 
concentration of 0.00, no previous crash or DWI, a day time collision, multiple vehicle 
involvement, survival time less than one hour, and a crash year of 1999 all served as 
referents.
Drug prevalence rates among drivers were assessed per year and by drug category or class. 
Any drug use was defined as testing positive for any one drug. Broad drug categories were 
grouped into drug classes including narcotics, depressants, stimulants, hallucinogens, 
cannabinoids, phencyclidine, or other. For specific, representative drugs, hydrocodone and 
oxycodone were grouped together separately from methadone as methadone is generally 
prescribed to treat opioid dependence (Mark et al. 2009). Benzodiazepines and barbiturates 
were used to assess depressants. Cocaine was used as a marker of illegal drug use because it 
is a controlled substance generally unattainable outside a healthcare institution.
Drug prevalence rates were determined by calculating the number of fatalities per drug 
category or class divided by the total number of drivers tested. These drug prevalence rates 
were presented graphically to depict trends over the 12-year period. The prevalence ratio 
was calculated by dividing the drug prevalence rates per drug category or class in 2009-2010 
by the rates in 1999-2000. The purpose of the prevalence ratio was to quantify the overall 
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trend of drug prevalence at the beginning and end of the study period. All drug prevalence 
rates and prevalence ratios were calculated using log binomial regression model with 
random effects. This hierarchical regression model used state as the grouping variable to 
assess the random effects of state reporting and the fixed effects of the collision year. All 
statistical analyses were run using SAS/STAT® software, version 9.3 (SAS Institute Inc. 
2010). The a priori level of statistical significance was 0.05 for all analyses.
2.2.1 Sensitivity analysis—Due to the differences in collision reporting amongst states, 
a sensitivity analysis was conducted. The sensitivity analysis investigated the effects of 
states’ overall drug testing percentages on the results. All analyses previously described 
were re-run using data from states that routinely tested 80% or more of their fatality injured 
drivers; the following states met this criterion: California, Hawaii, New Hampshire, New 
Jersey, New Mexico, Rhode Island, Washington, and West Virginia. The results from the 
original analysis and the sensitivity analysis were compared to determine if a bias in 
reporting existed.
3. Results
The descriptive characteristics of the fatally injured drivers with complete toxicological 
profiles are presented by test result status in Table 1. Of the 95,654 drivers included in the 
analysis, 23,500 (24.6%) tested positive for at least one drug. With the exception of the day 
of the week and survival time post-collision, all demographic characteristics were 
statistically significant. Of the total drivers tested, 87.5% were between the ages of 21-64 
years. Males were tested more often than females and tended to be of white, non-Hispanic 
race/ethnicity. Approximately 8% of the total drivers tested held commercial drivers’ 
licenses. The vast majority of participants were administered a blood test (85.5%) to assess 
drug presence. Of the total drivers tested, approximately 62% had blood alcohol 
concentrations equal to 0 g/dl, compared to 33% of the total drivers tested had blood alcohol 
concentrations ≥ 0.08 g/dl. Over 95% of the drivers tested had not been previously convicted 
of DWI, while over 84% had not been involved in a recent collision. Of the total drivers 
tested, the day of the crash was not significant with almost equal percentages occurring 
during the week as opposed to the weekend. Of the total drivers tested, single-vehicle 
collisions were more prevalent than multiple-vehicle collisions (51.6% vs. 48.4%, 
respectively). Approximately 67.2% of the total drivers tested met their demise within 1 
hour of crash, though this was not statistically significant (p=0.1519). Over the 12 year span, 
the total number of drivers tested steadily increased from 6,686 in 1999 to 7,032 in 2010 and 
this was significant (p= <0.0001). The results of the sensitivity analysis showed similar 
results (data not shown).
Table 2 presents the percentage of the population testing positive for drugs and the 
prevalence ratios for each demographic characteristic previously described. The prevalence 
ratio was shown to quantify whether the demographic characteristic/attribute was associated 
with either an increased or decreased occurrence of a drug positive result compared to the 
specified referent sub-group. Individuals aged <16, 55-64, and ≥65 years had a lower 
prevalence of drug positive results whereas individuals aged 21-24, 25-34, 35-44, and 45-54 
years all had higher prevalence of drug positive results. Females tended to test positive for 
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drugs slightly lower than males (PR=0.90; 95% CI 0.87, 0.92). Asians had the lowest 
prevalence of positive drug tests (PR=0.59; 95% CI 0.54, 0.65) compared to all other races. 
Both Hispanic ethnicity (PR=0.84 95% CI 0.81, 0.88) and commercial drivers (PR=0.87; 
95% CI 0.83, 0.90) had a lower prevalence of drug usage. Individuals with a BAC greater 
than 0.00 g/dl tended to test positive for drugs. Those with BAC concentrations between 
0.01-0.07 g/dl had the highest prevalence of drug positive test results (PR=1.52; 95% CI 
1.46, 1.59) followed by those with a BAC ≥0.08 g/dl (PR=1.30; 95% CI 1.27, 1.33). 
Individuals that had a previous DWI or crash within the past 3 years both tended to test 
positive for drugs. The presence of drugs was detected 28% higher in single vehicle 
collisions compared to multiple vehicle crashes (PR=1.28; 95% CI 1.24, 1.30). Interestingly, 
the prevalence of drug positive tests steadily increased from 1999-2010. While the number 
of drivers testing positive increased over this time span, the percentage testing positive for 
drugs increased from 18.1% in 1999 to 29.1% in 2010. The results of the sensitivity analysis 
showed similar results (data not shown).
The prevalence rates and ratios of drug involvement amongst these fatally injured drivers are 
presented in Table 3. From 1999-2000 to 2009-2010, the rates of drug involvement in fatally 
injured drivers in the U.S. dramatically shifted. Between these two time points, the number 
of fatally injured drivers whom tested positive for any drug use increased 49% (rate ratio, 
PR=1.49; 95% CI 1.42, 1.55). With the exception of hallucinogens, increases of drug 
prevalence rates were observed in virtually all broad categories of drugs from 1999-2000 to 
2009-2010. The largest increases were seen in narcotics (PR=2.73; 95% CI 2.41, 3.08) 
depressants (PR=2.01; 95% CI 1.80, 2.25), and cannabinoids (PR=1.99; 95% CI 1.84, 2.16). 
As for specific drugs, prescription drug use radically increased amongst fatally injured 
drivers between 1999-2000 and 2009-2010. The greatest increases in rate were seen for 
prescription opioids. The rate of hydrocodone and oxycodone present in fatally injured 
drivers was more than 6 times higher in 2009-2010 compared to 1999-2000 (PR=6.37; 95% 
CI 5.07,8.02), while methadone detection was over 4 times higher in 2009-2010 (PR=4.29; 
95% CI 2.88, 6.37). The rate of prescription benzodiazepines found in fatally injured drivers 
more than doubled in 2009-2010 compared to 1999-2000 (PR=2.27; 95% CI 2.00, 2.58). 
Barbiturates were the only class of prescription drugs to experience significant declines in 
rate (PR=0.53, 95% CI 0.37, 0.75). The rate of cocaine use in fatally injured drivers did not 
increase between 1999-2000 and 2009-2010 (PR=0.94, 95% CI 0.84, 1.06).
The results of the sensitivity analysis showed comparable results (not shown). The number 
of fatally injured drivers from these states whom tested positive for any drug use increased 
54% (PR=1.54; 95% CI 1.43, 1.66). The largest increases were seen in cannabinoids 
(PR=2.51; 95% CI 2.18, 2.89), depressants (PR=2.27; 95% CI 1.86, 2.78), and narcotics 
(PR=2.14; 95% CI 1.76, 2.60). The rate of hydrocodone and oxycodone present in fatally 
injured drivers from these states was over 5 times higher in 2009-2010 compared to 
1999-2000 (PR=5.34; 95% CI 3.63, 7.85), while methadone detection was over 3 times 
higher (PR=3.51; 95% CI 1.88, 6.55). Rates of prescription benzodiazepines more than 
doubled in drivers from these states (PR=2.46; 95% CI 1.94, 3.10). The rate of cocaine use 
in fatally injured drivers from these states did not increase between 1999-2000 and 
2009-2010 (PR=0.89, 95% CI 0.72, 1.11).
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Over the 12-year period, the patterns of drug involvement in fatally injured drivers also 
changed. From 1999-2010, the overall drug testing percent (Fig. 1) and number testing 
positive for any drug use steadily increased (Fig. 2). In general, narcotics, depressants, and 
cannabinoids steadily increased over this time span, while stimulants were on the rise until 
2005, but progressively declined (Fig. 3). As for specific drugs, rates of prescription 
oxycodone/hydrocodone, methadone, and benzodiazepines have also been steadily 
increasing (Fig. 4). Prescription barbiturates declined over the 12-year period. Contrarily, 
the occurrence of cocaine among fatally injured drivers steadily increased from 1999 to 
2005 and rapidly declined from 2006 to 2010. The results of the sensitivity analysis using 
states with over 80% testing percentage showed comparable results (data not shown).
4. Discussion
The principal finding of this study suggests that substance use is not only intensifying, but 
changing among those that drive under the influence of drugs in the U.S. With the exception 
of barbiturates, the occurrence of prescription drugs found in those involved in fatal traffic 
crashes has greatly increased from 1999 to 2010. The prevalence rates for narcotics, 
particularly hydrocodone, oxycodone, methadone, and depressants, such as benzodiazepines, 
have not only significantly risen, but are trending upwards. Contrarily, there appears to be a 
shift in illicit drug use. While drug prevalence rates for cannabinoids steadily increased from 
1999 to 2010, this substance is becoming legalized for medicinal use in several states. Illegal 
drugs appear to be declining in fatal traffic crashes. The pervasiveness of cocaine in fatal 
vehicle crashes initially increased, but has been rapidly declining since 2006. Considering 
these observed trends, there is evidence that a shift from illegal to prescription drugs may be 
occurring in those involved in fatal traffic crashes.
These findings are consistent with the current literature. In the U.S., prescription opioid 
analgesic use has dramatically increased since the 1990's (Joranson et al. 2000, Paulozzi et 
al. 2006a). From 1997 to 2005, the retail sales of prescription methadone, oxycodone, and 
hydrocodone have risen 933%, 588%, and 198%, respectively (Manchikanti 2007). Similar 
trends have been seen in other countries. From 2000-2005, both prescription opioid and 
benzodiazepine consumption increased 1.5-10% (Ravera et al. 2009), whereas methadone 
(Ravera et al. 2009) and barbiturate use remained relatively stable in Europe (Nicholas et al. 
2012).
The potential shift from illegal to prescription medication among those that drive under the 
influence may be evident in trends seen in emergency room departments and hospital 
admissions. Even though unintentional poisonings in the U.S. have dramatically increased, 
most of these incidences have been attributed to prescription drugs (Coben et al. 2010). 
From 1994-2002, emergency room cases involving narcotic analgesics increased 198% in 
comparison to cocaine, which only increased 39% (Paulozzi et al. 2006a). From 2004-2008, 
the number of emergency department visits due to the use of opioids and benzodiazepines 
increased 111% and 89%, respectively (Centers for Disease Control and Prevention 2010), 
which may be attributed to the fact that these two drugs are often used concomitantly (Jones 
et al. 2012). Similar trends have been observed in hospital admissions. Hospitalizations for 
poisonings due to prescription opioids, sedatives, and tranquilizers increased more than 65% 
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from 1999-2006 (Coben et al. 2010). Of these prescription medications, hospitalizations due 
to methadone and benzodiazepines increased 400% and 39%, respectively, compared to 
barbiturates, which decreased 41% (Coben et al. 2010). Death rates attributed to opioid 
analgesics was four times higher in 2008 compared to the rate in 1999 (Centers for Disease 
Control and Prevention 2011). Of these increases, deaths attributed to oxycodone and 
hydrocodone increased 57%, and methadone increased over 200% (Paulozzi et al. 2006b). 
Deaths from opioid analgesics surpassed overdose deaths attributed to cocaine (Centers for 
Disease Control and Prevention 2011).
Even though trends in prescription drug consumption and healthcare can be observed, a 
scarcity of information exists on the occurrence of driving under the influence of drugs in 
the U.S. According to the NHTSA, from 2005-2009, the presence of both prescription and 
illegal drugs in fatally injured drivers increased from 28% to 33% (National Highway 
Traffic Safety Administration 2010). A study conducted in Washington State showed that 
cocaine use increased 2% and benzodiazepine use increased 275% in fatally injured drivers 
(Schwilke et al. 2006). Even though illicit drug use prevailed over prescription substances in 
this analysis, the findings indicate that prescription medications are becoming more 
ubiquitous in drugged driving incidences (Schwilke et al. 2006). Another U.S. study 
indicated that polydrug use (i.e. the concurrent usage of two or more drugs) may also be 
problematic (Brady and Li 2013). The primary concern with multiple medication use is the 
interactive effects of the drugs which may impair the driver even more then if the substances 
were used separately. While epidemiologic data regarding polydrug use are scant, 
approximately 20% of drivers found under the influence of drugs tested positive for two or 
more substances (Brady and Li 2013). Combinations of alcohol with cannabis and/or 
stimulants, including cocaine and methamphetamine, were found most prevalent (Brady and 
Li 2013).
Despite the lack of U.S. data, studies from other countries may provide evidence of shifting 
trends in drugged driving. The frequency of drugged driving has steadily increased in 
countries such as Sweden, Finland, Norway, Switzerland, France, Scotland, and Australia 
(Drummer et al. 2003, Mura et al. 2006, Bernard et al. 2009, Jones et al. 2009, Officer 
2009, Ojaniemi et al. 2009, Senna et al. 2010, Blencowe et al. 2011, Bogstrand et al. 2011). 
Even though increases in illicit drug use, particularly cocaine (Mura et al. 2006, Senna et al. 
2010), have been noted, greater increases in prescription drugs have been seen (Drummer et 
al. 2003, Bernard et al. 2009, Officer 2009, Ojaniemi et al. 2009, Blencowe et al. 2011, 
Bogstrand et al. 2011). Although increases in opioid analgesics and methadone have been 
observed, the largest increases have been seen in benzodiazepine use while driving 
(Drummer et al. 2003, Bernard et al. 2009, Officer 2009, Ojaniemi et al. 2009, Blencowe et 
al. 2011, Bogstrand et al. 2011).
The shifting trends in drug use among those that drive under the influence may be partly 
explainable. Cocaine is still a widely-used recreational drug in the U.S., but its popularity 
appears to be waning compared to alcohol, tobacco, and cannabis (Degenhardt et al. 2008). 
Recent declines have been attributed to the discontinuation of use and/or demise of frequent 
users (Reuter 2006). Cocaine is not as popular with young adults as teens appear to be 
abusing prescription drugs (Friedman 2006). Cocaine's recent decline may be attributed to 
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changes in the price of the drug and more effective anti-drug policies (Costa Storti and De 
Grauwe 2009). Several societal and political changes may have contributed to the rise of 
prescription drugs among those that drive under the influence. Internet pharmacies have 
made obtaining prescription medications easier (Manchikanti 2007). In addition, numerous 
benzodiazepines and opioids came off patent protection from 2004-2008 enabling generic 
versions to be manufactured (Adis International 2002, Bailey et al. 2006, Srihari et al. 
2009). Generic drugs are typically less expensive making them more accessible to patients 
(Srihari et al. 2009). Healthcare policy initiatives may have exacerbated this problem. 
National initiatives to address the under-treatment of pain have been linked to the large 
increases in opioid prescriptions (Manchikanti 2007, Pletcher et al. 2008). Methadone use 
among drugged drivers may not have risen as quickly as other drugs partly because it is 
heavily regulated (Mark et al. 2009). Declines in barbiturate use among those that drive 
under the influence may be attributed to the development of newer, less toxic medications 
(Doghramji 2006).
The findings and implications of this study show that driving under the influence of drugs is 
a major public health concern in the U.S. As indicated by the observed trends, this problem 
will likely amplify. Awareness campaigns are needed to show both the public and healthcare 
providers that driving under the influence of drugs, including common prescription 
medications, may be hazardous. The need for more enforcement is likely necessary.
The strengths of this study are the use of multi-state data over a 12-year time span. Data 
obtained from fatally injured drivers is more likely to be comprehensive with greater 
chances of reportable drug test results compared to those simply injured or cited in a traffic 
collision. The weaknesses of this study are the limitations of the FARS data. As previously 
mentioned, not all drivers killed in fatal crashes were tested for drugs. This issue was 
addressed in the sensitivity analysis. In addition, only a maximum of three drugs can be 
documented per person in FARS, which could potentially be a bias in cases of multiple-drug 
involvement. These findings do not attempt to prove that the presence of drugs found in the 
fatally injured drivers caused the traffic fatalities or that the drugs identified were misused.
5. Conclusion
Among drivers killed in U.S. traffic crashes, the prevalence of drug use is rising and a shift 
from illegal to prescription medications may be occurring. While illegal substances, such as 
cocaine, have been declining, increases in narcotics and depressants were observed. The 
changes in trend may be a result of recent societal and political movements. These findings 
indicate that driving under the influence of drugs, particularly prescription medications, is a 
growing public health and traffic safety concern in the U.S.
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• Patterns of drug-involvement among drivers killed in traffic crashes are 
changing
• Drug-positive prevalence increased 49% from 1999-2000 to 2009-2010
• Prescription drug use by drivers in fatal traffic crashes has considerably risen
• The use of illegal drugs, such as cocaine, in fatal crashes has declined
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Overall drug testing percentage of states that tested ≥ 50% of their fatally injured drivers, 
United Statesa, 1999-2010
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Trends in any drug usage by year amongst all fatally injured drivers with a known drug test 
result, United Statesa, 1999-2010
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Trends in broad drug usage by year amongst all fatally injured drivers with a known drug 
test result, United Statesa, 1999-2010
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Trends in representative prescription and illicit drug use by year amongst all fatally injured 
drivers with a known drug test result, United Statesa, 1999-2010
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TABLE 1
Characteristics of fatally injured drivers with known drug test results, United States, 1999-2010.
Characteristic Drivers that tested positive 
for drugs (n=23,500)
Drivers that tested negative 
for drugs (n=72,154)
Total drivers tested 
(n=95,654)
No. of drivers % No. of drivers % No. of drivers % p-value
Age (in years)
<16 49 0.2 338 0.5 387 0.4 <0.0001
16-20 2,781 11.8 9,221 12.8 12,002 12.6
21-24 3,116 13.3 8,452 11.7 11,568 12.1
25-34 5,339 22.7 13,768 19.1 19,107 20.0
35-44 4,866 20.7 12,020 16.7 16,886 17.7
45-54 3,984 17.0 10,755 14.9 14,739 15.4
55-64 1,794 7.6 7,580 10.5 9,374 9.8
≥65 1,558 6.6 9,982 13.8 11,540 12.1
Unknown 13 38 51
Gender <0.0001
Female 4,999 21.3 17,100 23.7 22,099 23.1
Male 18,500 78.7 55,047 76.3 73,547 76.9
Unknown 1 7 8
Race <0.0001
White 18,143 87.0 52,707 84.7 70,850 85.3
African American 1,969 9.4 6,376 10.2 8,345 10.0
Asian 370 1.8 2,060 3.3 2,430 2.9
Native American 265 1.3 749 1.2 1,014 1.2
Other 101 0.5 356 0.6 457 0.6
Unknown 2,652 9,906 12,558
Ethnicity <0.0001
Hispanic 2,372 11.6 8,536 14.1 10,908 13.5
Non-Hispanic 18,056 88.4 52,061 85.9 70,117 86.5
Unknown 3,072 11,557 14,629
Professional driver <0.0001
Yes 1,611 6.9 5,878 8.3 7,489 7.9
No 21,589 93.1 65,221 91.7 86,810 92.1
Unknown 300 1,055
Type of Drug Test 
Administered
<0.0001
Urine 1,583 6.9 4,398 6.2 5,981 6.4
Blood 18,236 79.3 61,964 87.5 80,200 85.5
Urine and Blood 3,176 13.8 4,437 6.3 7,613 8.1
Unknown 505 1,355 1,860
Blood alcohol concentration 
(g/dl)
<0.0001
0 12,845 55.0 46,164 64.0 59,009 61.7
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Characteristic Drivers that tested positive 
for drugs (n=23,500)
Drivers that tested negative 
for drugs (n=72,154)
Total drivers tested 
(n=95,654)
No. of drivers % No. of drivers % No. of drivers % p-value
0.01-0.07 1,840 8.0 3,708 5.0 5,548 5.8
≥0.08 8,815 38.0 22,282 31.0 31,097 32.5




No 21,605 93.5 68,013 96.2 89,618 95.5
Yes 1,509 6.5 2,685 3.8 4,194 4.5
Unknown 386 1,456 1,842
Crash within past 3 years <0.0001
No 17,499 81.3 54,676 85.0 72,175 84.1
Yes 4,032 18.7 9,630 15.0 13,662 15.9
Unknown 1969 7,848 9,817
Day of crash 0.4910
Friday-Sunday 11,798 50.2 36,407 50.5 48,205 50.4
Monday-Thursday 11,700 49.8 35,733 49.5 47,433 49.6
Unknown 2 14 16
Time of crash <0.0001
Day (7:00am-6:59pm) 11,067 47.7 37,071 51.9 48,138 50.9
Night (7:00pm-6:59am) 12,117 52.3 34,369 48.1 46,486 49.1
Unknown 316 714 1,030
Number of vehicles involved <0.0001
1 13,532 57.6 35,833 49.7 49,365 51.6
≥2 9,968 42.4 36,321 50.3 46,289 48.4
Survival time after crash 0.1519
Within 1 hour 15,186 67.6 46,584 67.0 61,770 67.2
Beyond 1 hour 7,295 32.5 22,909 33.0 30,204 32.8
Unknown 1019 2661 3680
Year of crash <0.0001
1999 1,213 5.2 5,473 7.6 6,686 7.0
2000 1,369 5.8 5,510 7.6 6,879 7.2
2001 1,583 6.7 6,151 8.5 7,734 8.1
2002 1,667 7.1 5,992 8.3 7,659 8.0
2003 1,878 8.0 6,317 8.8 8,195 8.6
2004 1,972 8.4 6,007 8.3 7,979 8.3
2005 2,317 9.9 6,391 8.9 8,708 9.1
2006 2,395 10.2 6,942 9.6 9,337 9.8
2007 2,452 10.4 6,916 9.6 9,368 9.8
2008 2,357 10.0 6,155 8.5 8,512 8.9
2009 2,250 9.6 5,315 7.4 7,565 7.9
2010 2,047 8.7 4,985 6.9 7,032 7.4
a
DWI=driving while intoxicated
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TABLE 2
Prevalence and prevalence ratios for drug presence among fatally injured drivers with known drug test results, 
United 546 States, 1999-2010.
Characteristic No. of drivers (n=95,654) % of population positive for drugs Prevalence ratio (95% CI)
a
Age (in years)
<16 387 12.7 0.45 (0.35, 0.59)
16-20 12,002 23.2 0.83 (0.80, 0.86)
21-24 11,568 26.9 0.96 (0.93, 1.00)
25-34 19,107 27.9 1.00 (Reference)
35-44 16,886 28.8 1.03 (1.00, 1.07)
45-54 14,739 27.0 0.97 (0.93, 1.00)
55-64 9,374 19.1 0.68 (0.65, 0.72)
≥65 11,540 13.5 0.48 (0.46, 0.51)
Gender
Female 22,099 22.6 0.90 (0.87, 0.92)
Male 73,547 25.2 1.00 (Reference)
Race
White 70,850 25.6 1.00 (Reference)
African American 8,345 23.6 0.92 (0.88, 0.96)
Asian 2,430 15.2 0.59 (0.54, 0.65)
Native American 1,014 26.1 1.02 (0.92, 1.13)
Other 457 22.1 0.86 (0.73, 1.03)
Ethnicity
Hispanic 10,908 21.8 0.84 (0.81, 0.88)
Non-Hispanic 70,117 25.8 1.00 (Reference)
Professional driver
Yes 7,489 21.5 0.87 (0.83, 0.90)
No 86,810 24.9 1.00 (Reference)
Blood alcohol concentration (g/dl)
0 59,009 21.6 1.00 (Reference)
0.01-0.07 5,548 33.8 1.52 (1.46, 1.59)
≥0.08 31,097 28.3 1.31 (1.27, 1.33)
DWI conviction within past 3 years
b
No 89,618 24.1 1.00 (Reference)
Yes 4,194 36.0 1.49 (1.43, 1.56)
Crash within past 3 years
No 72,175 24.3 1.00 (Reference)
Yes 13,662 29.5 1.22 (1.18, 1.25)
Day of crash
Friday-Sunday 48,205 24.5 0.99 (0.97, 1.01)
Monday-Thursday 47,433 24.7 1.00 (Reference)
Time of crash
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Characteristic No. of drivers (n=95,654) % of population positive for drugs Prevalence ratio (95% CI)
a
Day (7:00am-6:59pm) 48,138 23.0 0.88 (0.86, 0.90)
Night (7:00pm-6:59am) 46,486 26.1 1.00 (Reference)
Number of vehicles involved
1 49,365 27.4 1.28 (1.24, 1.30)
≥2 46,289 21.5 1.00 (Reference)
Survival time after crash
Within 1 hour 61,770 24.6 1.00 (Reference)
Beyond 1 hour 30,204 24.2 0.98 (0.96, 1.01)
Year of crash
1999 6,686 18.1 1.00 (Reference)
2000 6,879 19.9 1.10 (1.02, 1.18)
2001 7,734 20.5 1.13 (1.05, 1.21)
2002 7,659 21.8 1.20 (1.12, 1.28)
2003 8,195 22.9 1.26 (1.18, 1.35)
2004 7,979 24.7 1.36 (1.28, 1.45)
2005 8,708 26.6 1.47 (1.38, 1.56)
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TABLE 3
Prevalence rates and ratios of drug involvement in fatally injured drivers with known drug test results, United 
States, 1999-2000, 2009-2010
Drugs 1999-2000 2009-2010




Any drug usage 2,582 190.3 4,297 294.4 1.49 (1.42, 1.55)
Broad drug categories
Narcotics 342 25.2 1,012 69.3 2.73 (2.41, 3.08)
Depressants 428 31.6 990 67.8 2.01 (1.80, 2.25)
Stimulants 918 67.7 1,031 70.6 1.05 (0.96, 1.14)
Hallucinogens 28 2.1 25 1.7 0.88 (0.51, 1.52)
Cannabinoid 785 57.9 1,706 116.9 1.99 (1.84, 2.16)
Phencyclidine 10 0.7 29 2.0 1.86 (0.86, 4.01)
Others 643 47.4 808 55.4 1.08 (0.98, 1.20)
Representative drugs or classes
Hydrocodone/Oxycodone 83 6.1 592 40.6 6.37 (5.07, 8.02)
Methadone 30 2.2 145 9.9 4.29 (2.88, 6.37)
Benzodiazepines 331 24.4 876 60.0 2.27 (2.00, 2.58)
Barbiturates 82 6.0 48 3.3 0.53 (0.37, 0.75)
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